Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations have improved dramatically with EGFR and ALK ty...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | 図書 |
| 出版事項: |
International Association of Physical Chemists (IAPC),
2016-10-01T00:00:00Z.
|
| 主題: | |
| オンライン･アクセス: | Connect to this object online. |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
| 請求記号: |
A1234.567 |
|---|---|
| 所蔵 1 | 利用可 |